What is GHK-Cu?
GHK-Cu is a copper complex of a tripeptide (a chain of three amino acids) found naturally in human plasma (the liquid part of blood), discovered in 1973 and used in cosmetics since the 1990s. Applied to the skin it has animal wound healing data and small human cosmetic studies showing improved skin elasticity, firmness, and fine lines, mostly industry associated and summarized in reviews by its discoverer. One small randomized trial of topical GHK-Cu after laser resurfacing found no difference in redness, wrinkles, or skin quality by blinded assessment, though patients using it rated their own skin higher. It is lawful as a cosmetic ingredient, but the injectable form sold online is an unapproved drug with no human trial; FDA lists injectable GHK-Cu as a withdrawn 503A nomination, so it is off Category 2 (FDA's list of compounding ingredients with significant safety risks) but not on the bulks list of ingredients pharmacies may use.
GHK-Cu is a naturally occurring tripeptide (glycyl-histidyl-lysine) complexed with copper(II); found in human plasma, saliva, and urine. It is also known as Copper peptide, GHK copper, Glycyl-L-histidyl-L-lysine copper, Gly-His-Lys-Cu, copper tripeptide-1, Prezatide copper, GHK-Cu peptide, GHK Cu, GHKCu.
How does it work?
GHK binds copper(II) with an affinity similar to albumin's copper transport site and delivers it to cells. In cell and animal models GHK-Cu attracts macrophages, mast cells, and endothelial cells to injury sites, increases synthesis of collagen, elastin, glycosaminoglycans, and decorin, modulates matrix metalloproteinases and their inhibitors, and suppresses inflammatory signals including NF-kB and TNF-alpha. Gene expression studies suggest it shifts expression of a large number of human genes toward a repair profile. These mechanisms come from in vitro and animal work; human data are limited to skin outcomes.
| Cluster | Tissue repair and healing |
|---|---|
| Routes | Topical cream or serum (cosmetic use, the only form with human data); Subcutaneous injection (as sold; no human data); Topical, intraperitoneal, and systemic (animal studies) |
| Conditions studied | Tendon injury and tendinopathy; Skin aging and cosmetic repair; Wound healing; Hair loss (androgenetic alopecia) |
| Record | v4, reviewed, verified Sep 30, 2026 |
GHK-Cu benefits: topical vs injected, what studies cover
The deciding study is a randomized trial of topical GHK-Cu (Miller 2006, PMID 16847171): patients were randomized after CO2 laser resurfacing to skin care with or without GHK-Cu and followed for 12 weeks, with redness, wrinkles, and skin quality rated by blinded evaluators and computer analysis. Thirteen patients completed it; there was no difference between groups in redness, wrinkles, or overall skin quality, though patients using GHK-Cu rated their own skin quality higher (P = .04). The grade is human RCT because a randomized human trial is indexed; the grade describes how the evidence was gathered, not whether GHK-Cu works, and this trial was small with negative objective results. Other human data are small cosmetic studies cited through reviews by the peptide's discoverer, animal studies show faster wound healing, and there is no human trial of injected GHK-Cu for any indication.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 1 | 13 |
| Human observational studies | 2 | n/a |
| Animal studies | 1 | n/a |
| All indexed studies | 4 | 13 |
Human evidence
One randomized trial is indexed, and it tested topical GHK-Cu: patients were randomized to skin care with or without GHK-Cu after CO2 laser resurfacing (13 patients completed, 12 weeks). Blinded evaluators and computer analysis found no difference in redness, wrinkles, or overall skin quality, though patients using GHK-Cu rated their skin quality higher (P = .04). Reviews also report controlled studies in aged skin in which topical GHK-Cu creams tightened loose skin, improved elasticity, skin density, and firmness, reduced fine lines and wrinkles, and reduced photodamage and hyperpigmentation, and describe wound healing activity in humans. Those studies are small, mostly cosmetic industry studies, and are cited through review articles rather than as separately indexed trials. No indexed human trial of subcutaneous GHK-Cu identified.
Animal evidence
GHK-Cu accelerated healing of skin wounds, hair follicles, gastrointestinal tract, and bone in rodent and pig models, induced systemic wound healing in rats, mice, and pigs, and improved healing of foot pads in dogs. In vitro it increased fibroblast and keratinocyte proliferation, restored replicative vitality to fibroblasts after radiation, stimulated nerve outgrowth and angiogenesis, and increased hair follicle size.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data2018 PMID 29986520 | Narrative reviewCell, animal, and human skin studies | Summarizes wound healing across skin, lung, bone, liver, and stomach in animals, and gene expression data suggesting broad regulation of repair and inflammation pathways | Evidence: Animal-only evidence |
| GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration2015 PMID 26236730 | Narrative reviewAnimal wound models and human cosmetic studies of topical GHK-Cu | Reports accelerated wound healing in rats, mice, pigs, and dogs and cosmetic study findings of tighter skin, improved elasticity and density, and fewer fine lines and wrinkles | Evidence: Human observational evidence |
| The human tri-peptide GHK and tissue remodeling2008 PMID 18644225 | Narrative reviewCell, animal, and human studies of GHK and GHK-Cu | Describes chemoattraction of repair cells, anti-inflammatory effects, increased collagen and elastin synthesis, and controlled studies in aged skin showing improved firmness and fewer wrinkles | Evidence: Human observational evidence |
| Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin2006 PMID 16847171 | Randomized controlled trial of skin care with or without topical GHK-Cu; blinded evaluators and computer analysis; 12 weeksn = 13 Patients after circumoral CO2 laser resurfacing | No significant difference between groups in redness, wrinkles, or overall skin quality by blinded or computer assessment; higher patient rated skin quality with GHK-Cu (P = .04) | Evidence: Human RCT evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Tendon injury and tendinopathy | Evidence: Animal-only evidence | Collagen synthesis and remodeling effects in animal and cell models; human data limited to skin. |
| Skin aging and cosmetic repair | Evidence: Human RCT evidence | One small randomized trial of topical GHK-Cu after laser resurfacing (13 completers) found no objective benefit on redness, wrinkles, or skin quality; other human data are small topical cosmetic studies, with extensive cell data on collagen and gene expression; no injectable trials. |
| Wound healing | Evidence: Human observational evidence | Small human studies of copper peptide dressings and extensive cell and animal data. |
| Hair loss (androgenetic alopecia) | Evidence: Animal-only evidence | Reviews describe larger hair follicles and follicle cell effects in lab and animal studies; common in cosmetic serums, but no indexed human hair loss trial. |
Is GHK-Cu legal in the United States?
FDA and compounding status
GHK-Cu has two regulatory tracks. As a cosmetic ingredient in topical products it can be sold without FDA premarket approval, as long as the product makes no drug claims. As a drug it is not FDA approved. For compounding, FDA treats it by route. GHK-Cu for non-injectable routes is in 503A Category 1 (under evaluation). Under FDA's interim policy, FDA does not intend to act against a 503A pharmacy or physician that compounds it for an identified patient on a prescription, if the ingredient comes from a registered manufacturer with a valid certificate of analysis and all other 503A conditions are met. GHK-Cu for injectable routes was in Category 2 and is now on FDA's list of withdrawn nominations. That list is outside any category and outside the interim policy, so as of the last verification date a 503A pharmacy has no federal basis to compound injectable GHK-Cu from bulk. FDA has said it intends to consult the Pharmacy Compounding Advisory Committee on GHK-Cu before the end of February 2027. FDA has also warned that 'research use only' labels do not make a product lawful when it is intended for use in people.
WADA status
WADA status unclear. The current prohibited list does not name this compound explicitly and its class status is not settled. Athletes should ask their anti-doping organization before use.
Regulatory timeline
- FDA
FDA lists BPC-157 and 16 other peptides as withdrawn from 503A Category 2
FDA's Category 2 page, current as of April 22, 2026, moved BPC-157, AOD-9604, CJC-1295, dihexa, DSIP, epitalon, injectable GHK-Cu, ipamorelin, KPV, LL-37, melanotan II, MOTS-c, PEG-MGF, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500) to a list of bulk drug substances nominated but withdrawn by their nominators. Withdrawal takes a substance off Category 2 but does not place it in Category 1, so FDA's interim compounding policy does not cover it, and it is not on the 503A bulks list. Ipamorelin acetate remains in 503B Category 2. Seven of the withdrawn peptides (BPC-157, KPV, TB-500, MOTS-c, semax, epitalon, and DSIP) were taken to the Pharmacy Compounding Advisory Committee in July 2026.
Full tracker for GHK-Cu or the category-wide tracker.
Email me when GHK-Cu's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of GHK-Cu used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Not established in human literature for injection. Human cosmetic studies applied topical creams and serums over 8 to 12 weeks according to the reviews; no human dose finding study for injected GHK-Cu exists.
Routes reported
| # | Route |
|---|---|
| 1 | Topical cream or serum (cosmetic use, the only form with human data) |
| 2 | Subcutaneous injection (as sold; no human data) |
| 3 | Topical, intraperitoneal, and systemic (animal studies) |
GHK-Cu side effects
Side effects
| # | Reported side effect |
|---|---|
| 1 | Topical: generally well tolerated in cosmetic studies; occasional irritation or contact sensitivity |
| 2 | Injectable: no systematic human safety data |
| 3 | Injection site pain and irritation reported anecdotally |
| 4 | Theoretical copper toxicity with large repeated injected doses (not documented) |
| 5 | Theoretical concern that a peptide that stimulates angiogenesis and cell proliferation could affect existing tumors (reviews also report anti-cancer activity in vitro; unresolved) |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal human interaction studies exist |
| 2 | Topical vitamin C and strong acids may destabilize the copper complex in a formulation (formulation issue, not a drug interaction) |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Known copper metabolism disorder such as Wilson disease (theoretical, injected form) |
| 2 | Pregnancy and breastfeeding for the injectable (no data) |
| 3 | Competitive athletes should avoid the injectable pending clarification of WADA status |
How do people access GHK-Cu legally?
Typical cost: Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Access options
Available
Topical cosmetic products containing GHK-Cu are sold over the counter without a prescription, as long as they make only cosmetic claims.
Not available
No lawful compounded path for injectable GHK-Cu today: FDA lists it as a withdrawn 503A nomination, so it is off Category 2 but not on the 503A bulks list, and a 503A pharmacy has no federal basis to compound it from bulk.
Not available
Not available as an FDA approved drug; injectable products labeled research use only are unapproved drugs when sold for human use.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare GHK-Cu
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [10] [11] [12]
For GHK-Cu it depends on the route. Injectable GHK-Cu is on FDA's list of withdrawn nominations, outside FDA's interim policy, so a pharmacy has no federal basis to compound it. Non-injectable forms, such as creams, are in FDA's Category 1, where FDA's interim policy lets a licensed pharmacy compound them on a prescription while FDA decides whether to list them. [4] [13] [14]
What FDA found
- April 2020: FDA named GHK-Cu among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. The letter does not say which route. [11]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [10] [13] [15] [16] [17] [18]
What that means for you
- A pharmacy that compounds injectable GHK-Cu is taking a regulatory risk: it has no federal basis to do so. [10] [13]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [18]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [19]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [20] [21]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [13]
- Insurance rarely covers it, so you usually pay cash.
- For tested athletes, WADA status is unclear; ask your anti-doping organization before any use. [6]
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound injectable GHK-Cu, with or without a prescription. [4]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [22] [23] [24]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [12] [24] [25]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [18] [26] [27] [28] [29] [30]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [18]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [22]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [12]
- Pharmacy: Is this made for me on a prescription written in my name? [25]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [12] [24]
- Prescriber: What is the legal basis for a pharmacy to compound GHK-Cu? Is it FDA approved or on the 503A bulks list? [4] [18]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [12]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [19]
Blends that contain GHK-Cu
GHK-Cu is sold in premixed blends under the names below. No blend has been tested as a combination, and a mix is only as lawful as its least lawful ingredient.
Frequently asked questions
What does GHK-Cu do?
GHK-Cu is a small peptide from human plasma (the liquid part of blood) that binds copper and delivers it to cells. In cell and animal studies it draws repair cells to wounds, increases production of collagen, elastin, and glycosaminoglycans (the proteins and gel-like molecules that give skin its structure), and dampens inflammatory signals, and animal wounds heal faster with it. In people, the evidence is limited to skin products applied to the surface, where small cosmetic studies report firmer, more elastic skin and fewer fine lines. [1] [2] [3]
Are copper peptides the same as GHK-Cu?
Mostly, but not always. Copper peptide is a skin care label for ingredients that pair copper with a short peptide, and GHK-Cu (listed on labels as copper tripeptide-1) is the one the research is about. A product sold as copper peptides may contain GHK-Cu at an unstated strength or a different copper complex, and results from GHK-Cu studies apply only to GHK-Cu. [2] [3]
Topical vs injected GHK-Cu: what do studies cover?
Every human study is topical. Reviews summarize small cosmetic studies of creams and serums in aged or sun damaged skin, and one independent randomized trial after laser resurfacing found no objective improvement over skin care without GHK-Cu, only higher patient satisfaction. Injected GHK-Cu has animal data from systemic dosing but no human study of any kind, so its effects and safety in people are unknown. Topical products sold without drug claims are regulated as cosmetics; injectable GHK-Cu has no federal basis to be compounded from bulk. [1] [2] [4] [7]
What are the side effects of GHK-Cu, and is it safe?
Topical GHK-Cu is generally well tolerated in cosmetic studies, with occasional irritation. The injectable has no systematic human safety data; anecdotal reports mention injection site pain, and copper overload from repeated large injected doses is a theoretical concern. Reviews report both pro-repair and anti-cancer activity in cell studies, so the effect on existing tumors is unresolved. Unapproved injectable products also carry identity and purity risks. [1] [2] [8]
Is GHK-Cu FDA approved?
No. GHK-Cu is not an FDA approved drug and not a component of one. As a cosmetic ingredient in creams and serums it is lawfully sold without FDA approval as long as the products make only cosmetic claims. Injectable GHK-Cu is a withdrawn 503A nomination: it is off Category 2 but not on the 503A bulks list and was not reviewed by the advisory committee in July 2026, so a 503A pharmacy has no federal basis to compound it from bulk. Injectable vials sold as research chemicals for human use are unapproved drugs. [4] [5] [9]
Does GHK-Cu work for skin aging and wrinkles?
The topical evidence is encouraging but thin. Reviews describe controlled cosmetic studies in which GHK-Cu creams tightened loose skin, improved elasticity, firmness, and density, and reduced fine lines, wrinkles, and photodamage over 8 to 12 weeks. Those studies are small, industry associated, and cited through reviews written by the peptide's discoverer. The one randomized trial identified, in 13 patients after laser resurfacing, found no difference in redness, wrinkles, or skin quality by blinded assessment, although patients using GHK-Cu rated their own skin higher. PeptideAgent grades the evidence human RCT because that randomized trial is indexed; the grade describes how the evidence was gathered, not whether the peptide works. [2] [3] [7]
Does GHK-Cu help hair growth?
Reviews report that GHK-Cu increases hair follicle size in animal and ex vivo models, which is the basis for copper peptide hair products. No indexed randomized human trial of GHK-Cu for hair loss was identified, so the human claim is unproven. [2] [3]
Is GHK-Cu banned by WADA?
It is not named on the WADA Prohibited List, and a topical cosmetic is not a doping concern. Injected GHK-Cu is a pharmacological substance with no approval by any health authority for therapeutic use, which is the definition WADA uses for section S0 (non-approved substances), so athletes should treat the injectable as prohibited and check with their anti-doping organization. [6]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
From the blog
- Topical vs injectable GHK-Cu: what the evidence shows
Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and is not on the 503A bulks list. Evidence, absorption, safety, and legality compared.
- GLOW peptide before and after: what the evidence shows
No study has measured GLOW peptide before and after results. What each ingredient's human evidence shows for skin and hair, documented side effects, and the blend's legal status.
- Minoxidil side effects: topical, oral, shedding, and pets
Minoxidil side effects differ by form: scalp irritation and unwanted facial hair with topical use, body hair and fluid retention with oral use. Plus shedding, pregnancy, and the danger to cats.
- Oral minoxidil for hair loss: evidence and side effects
Low-dose oral minoxidil is an off-label hair loss treatment. What the FDA label for the blood pressure tablet says, what the hair loss trials found, and the side effects they reported.
- Copper peptides for hair: what the studies show
Does GHK-Cu help with hair growth? Copper peptides enlarge hair follicles in lab and mouse studies, but no randomized trial of GHK-Cu alone for hair loss exists. How they compare with minoxidil.
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
More on the blog
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018PubMed 29986520, 2018
- [2]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015PubMed 26236730, 2015
- [3]Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008PubMed 18644225, 2008
- [4]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [5]FDA: Is it a cosmetic, a drug, or both? (or is it soap?)FDA, 2024
- [6]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [7]Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006PubMed 16847171, 2006
- [8]Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med 2026PubMed 41966639, 2026
- [9]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [10]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 30). GHK-Cu: evidence, legality, and access. https://peptideagent.ai/peptides/ghk-cu- HTML link
<a href="https://peptideagent.ai/peptides/ghk-cu">GHK-Cu: evidence, legality, and access</a>, PeptideAgent, updated September 30, 2026.